Discussing the BTK inhibitor landscape for CLL and SLL with a focus on the Phase 3 AMPLIFY study of acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo

Executed on:Feb 5, 2025 4:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: UCI IrvineHematologist and Oncologist, and Associate Professor — Division of Hematology-Oncology, Department of Medicine, UCI School of Medicine.
Currently manages 200 patients with CLL annually 
Specializes in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), which has been her research focus for more than a decade as a principal investigator of numerous clinical trials of novel agents that have improved the care of these patients.

Interview Goal

On this call we will be discussing the developing Bruton tyrosine kinase (BTK) inhibitor landscape for CLL and SLL with a primary focus on the recent data from the Phase 3 AMPLIFY study of Acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo presented at ASH 2024. We will also be discussing BTK Degraders NX-5948 vs. BGB-16673.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.